Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.

The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.

The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.

The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.

The company said treatment with tegoprubart was generally well-tolerated.

Eledon shares rose 11% in recent Tuesday trading.

Price: 3.75, Change: +0.38, Percent Change: +11.28